The iPhone maker's shares [rallied for a second day]( ...

Eli Lilly's experimental GLP-1 pill shows promise in a Phase Three trial, helping users lose an average of 12% of body weight ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...

The Red Angus Association of America has awarded scholarships to six youth leaders for their achievements in agriculture, academics, and service.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns ...

Stocks are rising on Wall Street, even as President Donald Trump’s latest tariffs kicked into effect on dozens of countries.

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

Eli Lilly (LLY) stock hits a 52-week low as concerns over its weight-loss drug trial overshadow strong Q2 2025 results. Read ...

Shares of Eli Lilly (NYSE: LLY) were plunging 14.8% as of 11:14 a.m. ET on Thursday. The big drugmaker reported results for ...

Novo Nordisk's flagship product is semaglutide. Sold under the names Ozempic and Wegovy, it's one of the leading GLP-1 ...